FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Washington, D.C. 20549

OMB APPROVAL												
OMB Number:	3235-0287											

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person*  Morisset Valerie					2. Issuer Name and Ticker or Trading Symbol Eliem Therapeutics, Inc. [ ELYM ]									(Ched	ck all app Direc	licable) tor	ng Person(s) to Is		vner
(Last) C/O ELI	(Fir	st) (MAPEUTICS, INC	Middle)		3. Date of Earliest Transaction (Month/Day/Year) 07/12/2024									V	below	er (give title /) EVP, R&D	) AN	Other (s below) D CSO	вреспу 
(Street) WILMINGTON DE 19808 (City) (State) (Zip)				4. If Amendment, Date of Original Filed (Month/Day/Year)  Rule 10b5-1(c) Transaction Indication								6. Ind Line)							
					Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intend satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.									nded to					
		Table	I - No	n-Deriva	tive S	Secui	rities	Acq	uired,	Dis	posed of	, or B	enef	iciall	y Own	ed			
1. Title of Security (Instr. 3)  2. Transac Date (Month/Da				Execution Date		Date,	Transaction Disposed (Code (Instr. 5)		es Acquired (A) Of (D) (Instr. 3, 4		4 and Secur Benef		ities Ficially (I d Following (I		n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
									Code	v	Amount	(A) or (D) Pr		rice	Transaction(s) (Instr. 3 and 4)				(IIIStr. 4)
Common Stock 07/12/2					2024		S		50,000	D	)   \$	<b>57.07</b>	07 294,683			D			
Common Stock 07/15/2				2024				S		42,377	D	9	67.01	252,306			D		
		Tal									osed of, o				Owne	t		,	
1. Title of Derivative Security (Instr. 3)	ative Conversion Date Execution Date, ity or Exercise (Month/Day/Year) if any			4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		De Se (In	Price of erivative ecurity estr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amou or Numb of Share	er					

**Explanation of Responses:** 

/s/ Alan Hambelton, Attorney- 07/16/2024

in-Fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.